2026-05-12

Semaglutide taken on scan day ruins PET/CT imaging quality

Semaglutide is everywhere now — diabetes control, weight loss, clinical trials, compounding vials. Millions of people inject it weekly. Nobody mentioned it could wreck your cancer scan.

What happened. A 48-year-old man with diabetes got a PET/CT for suspected cancer. First scan, no recent semaglutide: clean muscle signal, clear lesions visible in the nasopharynx and lymph nodes. Thirteen months later, lower back pain, another scan scheduled. This time he injected semaglutide the same morning. The scan lit up everywhere — diffuse muscle uptake, the kind that makes lesions invisible. Six days off semaglutide, third scan: muscles normalized, multiple hypermetabolic lesions suddenly clear.

Why it matters. PET/CT uses 18F-FDG, a radioactive glucose tracer, to find cancer. Tumors eat glucose. So do muscles — if they're metabolically active. Semaglutide is a GLP-1 agonist. It changes how your body handles glucose. Inject it before a scan and your muscles start pulling FDG out of circulation, turning your imaging into static.

What the paper says. This is the first reported case. EJNMMI Research, May 2026, Hong et al. One patient, three scans, clear pattern. The authors recommend stopping semaglutide at least 24 hours before PET/CT in diabetic patients. They don't say how long is safe. They don't say if this applies to tirzepatide, retatrutide, or other GLP-1 drugs. One case doesn't answer those questions.

If you're scheduled for imaging. Ask your ordering physician. PET/CT is used to stage cancer, monitor treatment, hunt for metastases. A ruined scan means a delay, another appointment, more radiation exposure, and in some cases a missed diagnosis.

Bukowski isn't telling you to stop your medication. He's telling you nobody warned this patient, and the information is now in the literature.